We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
Read MoreHide Full Article
Key Takeaways
BSX Neuromodulation posted 15% organic sales growth, led by pain management gains.
Boston Scientific's Intracept gained traction with five-year data supporting chronic low back pain treatment.
BSX saw strong Cartesia X adoption and rising Illumina 3D uptake across the United States.
Boston Scientific’s (BSX - Free Report) Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
Neuromodulation delivered a strong quarter, with organic sales increasing 15% and the comprehensive portfolio posting low double-digit growth. The pain management business grew in the mid-teens, supported partially by a strong contribution from the acquisition of Nalu (completed in late January 2026).
Intracept continued to gain momentum, driven by compelling five-year clinical data demonstrating its long-term efficacy and cost-effectiveness in treating chronic low back pain. Within DBS, adoption of the Cartesia X leads remained strong, while the Illumina 3D programming algorithm saw accelerating uptake across the United States.
Boston Scientific continues to invest in neuromodulation platforms while strengthening its commercial capabilities. The Neuromodulation segment showed improvement, supported by organic contributions from acquisitions such as Relievant and Axonics in 2025. Management expects the Neuromodulation business to grow faster than the broader market over time.
Updates on BSX’s Neuromodulation Competitors
NeuroPace (NPCE - Free Report) delivered a strong neuromodulation business performance in fourth-quarter 2025, driven by continued adoption of its responsive neurostimulation (RNS) platform for drug-resistant epilepsy. The company also accelerated development of AI-enabled neuromodulation tools like Seizure ID — an AI-driven platform designed to analyze intracranial EEG recordings, identify seizure activity, and improve physician workflow efficiency.
Medtronic's (MDT - Free Report) Neuromodulation business reported 4% growth in the fiscal third quarter, with the ongoing rollout of its Inceptiv spinal cord stimulation (SCS) system and BrainSense adaptive DBS (aDBS) platforms. Inceptiv spinal cord stimulation system is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. With neuromodulation systems’ adoption expanding across major geographies, the company remains well positioned for sustained momentum and long-term leadership in neuromodulation and neurosurgical innovation.
BSX Stock Price Performance
Shares of Boston Scientific have lost 45.2% over the past year compared with the industry’s decline of 29%. The S&P 500 composite has grown 35.4% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 3.76X, above the industry median of 3.09X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has moved south 2% over the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
Key Takeaways
Boston Scientific’s (BSX - Free Report) Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
Neuromodulation delivered a strong quarter, with organic sales increasing 15% and the comprehensive portfolio posting low double-digit growth. The pain management business grew in the mid-teens, supported partially by a strong contribution from the acquisition of Nalu (completed in late January 2026).
Intracept continued to gain momentum, driven by compelling five-year clinical data demonstrating its long-term efficacy and cost-effectiveness in treating chronic low back pain. Within DBS, adoption of the Cartesia X leads remained strong, while the Illumina 3D programming algorithm saw accelerating uptake across the United States.
Boston Scientific continues to invest in neuromodulation platforms while strengthening its commercial capabilities. The Neuromodulation segment showed improvement, supported by organic contributions from acquisitions such as Relievant and Axonics in 2025. Management expects the Neuromodulation business to grow faster than the broader market over time.
Updates on BSX’s Neuromodulation Competitors
NeuroPace (NPCE - Free Report) delivered a strong neuromodulation business performance in fourth-quarter 2025, driven by continued adoption of its responsive neurostimulation (RNS) platform for drug-resistant epilepsy. The company also accelerated development of AI-enabled neuromodulation tools like Seizure ID — an AI-driven platform designed to analyze intracranial EEG recordings, identify seizure activity, and improve physician workflow efficiency.
Medtronic's (MDT - Free Report) Neuromodulation business reported 4% growth in the fiscal third quarter, with the ongoing rollout of its Inceptiv spinal cord stimulation (SCS) system and BrainSense adaptive DBS (aDBS) platforms. Inceptiv spinal cord stimulation system is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. With neuromodulation systems’ adoption expanding across major geographies, the company remains well positioned for sustained momentum and long-term leadership in neuromodulation and neurosurgical innovation.
BSX Stock Price Performance
Shares of Boston Scientific have lost 45.2% over the past year compared with the industry’s decline of 29%. The S&P 500 composite has grown 35.4% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 3.76X, above the industry median of 3.09X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has moved south 2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.